Page 4 - Chong Kun Dang Pharmaceutical Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Insights on the Biosimilars Global Market to 2025 - Featuring Amgen, Cipla and Pfizer Among Others
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Worldwide Biosimilars Industry to 2025 - by Type of Biosimilar, Therapeutic Application and Region
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
S. Korea s Nafabeltan gets clinical approval for COVID-19 treatment in Australia |
Nafabeltan, which is currently used as a blood anticoagulant and acute pancreatitis treatment. (Chong Kun Dang Pharmaceutical Corp.)
South Korean drug firm Chong Kun Dang Pharmaceutical Corp. said Monday that it has won approval from Australia s drug authorities to begin a phase three clinical trial for coronavirus treatment with its acute pancreatitis drug.
The drug, Nafabeltan, will be administered to patients as part of the Australian government-led clinical study to find a COVID-19 treatment. The drug is currently used as a blood anticoagulant and acute pancreatitis treatment.
The Australian COVID-19 Trial, also known as ASCOT, is a randomized control trial that involves 2,500 patients in over 60 hospitals across the country alongside 12 hospitals in New Zealand with the participation of global pharmaceutical firms.